PrEP prescriptions, case management, and financial assistance available at Teton County Health Department. Call 307-733-6401 to talk to make an appointment to find out more!
From the CDC (https://www.cdc.gov/hiv/clinicians/prevention/prep.html):
What is PrEP?
PrEP is short for pre-exposure prophylaxis. It is the use of antiretroviral medication to prevent acquisition of HIV infection. PrEP is used by people without HIV who are at risk of being exposed to HIV through sexual contact or injection drug use. Two medications have been approved for use as PrEP by the FDA. Each consists of two drugs combined in a single oral tablet taken daily:
- Emtricitabine (F) 200 mg in combination with tenofovir disoproxil fumarate (TDF) 300 mg (F/TDF – brand name Truvada®)
- Emtricitabine (F) 200 mg in combination with tenofovir alafenamide (TAF) 25 mg (F/TAF – brand name Descovy®)
These medications are approved to prevent HIV infection in adults and adolescents weighing at least 35 kg (77 lb) as follows:
- Daily oral PrEP with F/TDF is recommended to prevent HIV infection among all persons at risk through sex or injection drug use.
- Daily oral PrEP with F/TAF is recommended to prevent HIV infection among persons at risk through sex, excluding people at risk through receptive vaginal sex. F/TAF has not yet been studied for HIV prevention for receptive vaginal sex.
PrEP should be considered part of a comprehensive prevention plan that includes a discussion about adherence to PrEP, condom use, other sexually transmitted infections (STIs), and other risk reduction methods.
What are the guidelines for prescribing PrEP?
Comprehensive guidelines for prescribing PrEP have been published by the Centers for Disease Control and Prevention (CDC) in A Clinical Practice Guidelinepdf icon, including a Clinical Providers’ Supplementpdf icon.
The Clinical Providers’ Supplement contains additional tools for clinicians providing PrEP, such as a patient/provider checklist, patient information sheets, provider information sheets, a risk incidence assessment, supplemental counseling information, billing codes, and practice quality measures. If questions arise or if prescribing advice is needed, clinicians should consult the National Clinicians Consultation Center PrEP Line @ 1-855-448-7737 (9:00 AM – 8:00 PM EST).
The U.S. Preventive Services Task Force has given PrEP a grade A recommendation. This grade indicates that their review found that there is high certainty that the net benefit of this service is substantial. For more information, view the full recommendation rationale at www.uspreventiveservicestaskforce.orgexternal icon.
Who can prescribe PrEP?
Any licensed prescriber can prescribe PrEP. Specialization in infectious diseases or HIV medicine is not required. In fact, primary care providers who routinely see people at risk for HIV acquisition should consider offering PrEP to all eligible patients.
To whom should I offer PrEP?
PrEP is for people without HIV who are at risk of acquisition from sex or injection drug use. People at risk who should be assessed for PrEP include:
- Sexually active gay and bisexual men without HIV
- Sexually active heterosexual men and women without HIV
- Sexually active transgender persons without HIV
- Persons without HIV who inject drugs
- Persons who have been prescribed non-occupational post-exposure prophylaxis (PEP) and report continued risk behavior, or who have used multiple courses of PEP